IL17A and inflammatory bowel disease: Another study found that TNFi therapy in psoriasis and IBD patients led to increased peripheral IFN-γ, IL-17, IL-10 and the proliferative response of CD4+ T-cells to T-cell receptor stimulation, while biopsied target tissues showed decreased Th1/Th17 cytokines and inflammatory genes [196].